HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections.

Abstract
Viral infections cause life-threatening disease in immunocompromised patients and especially following transplantation. T cell receptor (TCR) engineering redirects specificity and can bring significant progress to emerging adoptive T cell transfer (ACT) approaches. T cell epitopes are well described, although knowledge is limited on which TCRs mediate protective immunity. In this study, refractory adenovirus (AdV) infection after hematopoietic stem cell transplantation (HSCT) was treated with ACT of highly purified Hexon5-specific T cells using peptide major histocompatibility complex (pMHC)-Streptamers against the immunodominant human leukocyte antigen (HLA)-A∗0101-restricted peptide LTDLGQNLLY. AdV was successfully controlled through this oligoclonal ACT. Novel protective TCRs were isolated ex vivo and preclinically engineered into the TCR locus of allogeneic third-party primary T cells by CRISPR-Cas9-mediated orthotopic TCR replacement. Both TCR knockout and targeted integration of the new TCR in one single engineering step led to physiological expression of the transgenic TCR. Reprogrammed TCR-edited T cells showed strong virus-specific functionality such as cytokine release, effector marker upregulation, and proliferation capacity, as well as cytotoxicity against LTDLGQNLLY-presenting and AdV-infected targets. In conclusion, ex vivo isolated TCRs with clinical proven protection through ACT could be redirected into T cells from naive third-party donors. This approach ensures that transgenic TCRs are protective with potential off-the-shelf use and widened applicability of ACT to various refractory emerging viral infections.
AuthorsTanja A Stief, Theresa Kaeuferle, Thomas R Müller, Michaela Döring, Lena M Jablonowski, Kilian Schober, Judith Feucht, Kevin M Dennehy, Semjon Willier, Franziska Blaeschke, Rupert Handgretinger, Peter Lang, Dirk H Busch, Tobias Feuchtinger
JournalMolecular therapy : the journal of the American Society of Gene Therapy (Mol Ther) Vol. 30 Issue 1 Pg. 198-208 (01 05 2022) ISSN: 1525-0024 [Electronic] United States
PMID34058386 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightPublished by Elsevier Inc.
Chemical References
  • Receptors, Antigen, T-Cell
Topics
  • Adoptive Transfer
  • Humans
  • Immunotherapy, Adoptive
  • Receptors, Antigen, T-Cell (genetics)
  • T-Lymphocytes
  • Virus Diseases

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: